Search Results - "PRABHALA, RAO H."

Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma by Prabhala, Rao H., Pelluru, Dheeraj, Fulciniti, Mariateresa, Prabhala, Harsha K., Nanjappa, Puru, Song, Weihua, Pai, Christine, Amin, Samir, Tai, Yu-Tzu, Richardson, Paul G., Ghobrial, Irene M., Treon, Steven P., Daley, John F., Anderson, Kenneth C., Kutok, Jeffery L., Munshi, Nikhil C.

“…Elevated cytokines in bone marrow (BM) micro-environment (interleukin-6 [IL-6], transforming growth factor-beta [TGF-β], and IL-1β) may play an important role…”
Get full text

CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesis by Nandi, Bisweswar, Pai, Christine, Huang, Qin, Prabhala, Rao H, Munshi, Nikhil C, Gold, Jason S

“…Interactions between the inflammatory chemokine CCL20 and its receptor CCR6 have been associated with colorectal cancer growth and metastasis, however, a…”
Get full text

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma by Jinushi, Masahisa, Vanneman, Matthew, Munshi, Nikhil C, Tai, Yu-Tzu, Prabhala, Rao H, Ritz, Jerome, Neuberg, Donna, Anderson, Kenneth C, Carrasco, Daniel Ruben, Dranoff, Glenn

“…Monoclonal gammopathy of undetermined significance (MGUS) is a common disorder of aging and a precursor lesion to full-blown multiple myeloma (MM). The…”
Get full text

Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma by Talluri, Srikanth, Samur, Mehmet K., Buon, Leutz, Kumar, Subodh, Potluri, Lakshmi B., Shi, Jialan, Prabhala, Rao H., Shammas, Masood A., Munshi, Nikhil C.

“…Multiple myeloma (MM) is a heterogeneous disease characterized by significant genomic instability. Recently, a causal role for the AID/APOBEC deaminases in…”
Get full text

Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages by Nandi, Bisweswar, Shapiro, Mia, Samur, Mehmet K., Pai, Christine, Frank, Natasha Y., Yoon, Charles, Prabhala, Rao H., Munshi, Nikhil C., Gold, Jason S.

“…Interactions between the inflammatory chemokine CCL20 and its receptor CCR6 have been implicated in promoting colon cancer; however, the mechanisms behind this…”
Get full text

Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation by Gulla, Annamaria, Morelli, Eugenio, Samur, Mehmet K, Botta, Cirino, Hideshima, Teru, Bianchi, Giada, Fulciniti, Mariateresa, Malvestiti, Stefano, Prabhala, Rao H, Talluri, Srikanth, Wen, Kenneth, Tai, Yu-Tzu, Richardson, Paul G, Chauhan, Dharminder, Sewastianik, Tomasz, Carrasco, Ruben D, Munshi, Nikhil C, Anderson, Kenneth C

“…Proteasome inhibitor bortezomib induces apoptosis in multiple myeloma (MM) cells, and has transformed patient outcome. Using as well as immunodeficient and…”
Get full text

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device by Qasaimeh, Mohammad A., Wu, Yichao C., Bose, Suman, Menachery, Anoop, Talluri, Srikanth, Gonzalez, Gabriel, Fulciniti, Mariateresa, Karp, Jeffrey M., Prabhala, Rao H., Karnik, Rohit

“…The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of…”
Get full text

CCL20 induces colorectal cancer neoplastic epithelial cell proliferation, migration, and further CCL20 production through autocrine HGF-c-Met and MSP-MSPR signaling pathways by Nandi, Bisweswar, Del Valle, Jonathan Pastrana, Samur, Mehmet K, Gibbons, Allison J, Prabhala, Rao H, Munshi, Nikhil C, Gold, Jason S

“…CCL20-CCR6 interactions promote colorectal cancer through direct effects on neoplastic epithelial cells and through modulating the tumor microenvironment. The…”
Get full text

Immune Therapies by Prabhala, Rao H., PhD, Munshi, Nikhil C., MD

“…Immune cells with specific functions and abilities are vital to cancer treatment prevention. Although there have been many accomplishments made in the areas of…”
Get full text

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome by Driscoll, James J., Pelluru, Dheeraj, Lefkimmiatis, Konstantinos, Fulciniti, Mariateresa, Prabhala, Rao H., Greipp, Philip R., Barlogie, Bart, Tai, Yu-Tzu, Anderson, Kenneth C., Shaughnessy, John D., Annunziata, Christina M., Munshi, Nikhil C.

“…Multiple myeloma (MM) is a plasma cell neoplasm that proceeds through a premalignant state of monoclonal gammopathy of unknown significance; however, the…”
Get full text

Dysfunctional T regulatory cells in multiple myeloma by Prabhala, Rao H., Neri, Paola, Bae, Jooeun E., Tassone, Pierfrancesco, Shammas, Masood A., Allam, Charles K., Daley, John F., Chauhan, Dharminder, Blanchard, Elizabeth, Thatte, Hemant S., Anderson, Kenneth C., Munshi, Nikhil C.

“…Multiple myeloma (MM) is characterized by the production of monoclonal immunoglobulin and is associated with suppressed uninvolved immunoglobulins and…”
Get full text

Deficiency of IL-17A, but not the prototypical Th17 transcription factor RORγt, decreases murine spontaneous intestinal tumorigenesis by Shapiro, Mia, Nandi, Bisweswar, Pai, Christine, Samur, Mehmet K., Pelluru, Dheeraj, Fulciniti, Mariateresa, Prabhala, Rao H., Munshi, Nikhil C., Gold, Jason S.

“…While inflammation has been associated with the development and progression of colorectal cancer, the exact role of the inflammatory Th17 pathway remains…”
Get full text

Deficiency of the immunostimulatory cytokine IL-21 promotes intestinal neoplasia via dysregulation of the Th1/Th17 axis by Shapiro, Mia, Nandi, Bisweswar, Gonzalez, Gabriel, Prabhala, Rao H, Mashimo, Hiroshi, Huang, Qin, Frank, Natasha Y, Munshi, Nikhil C, Gold, Jason S

“…IL-21 has reported activity in promoting both Th1 and Th17 immune responses. Its role in sporadic human colorectal cancer is unknown. We aimed to delineate the…”
Get full text

A Phase II trial of weekly bortezomib and dexamethasone in veterans with newly diagnosed multiple myeloma not eligible for or who deferred autologous stem cell transplantation by Girnius, Saulius K., Lee, Saem, Kambhampati, Suman, Rose, Michal G., Mohiuddin, Abid, Houranieh, Antoun, Zimelman, Abraham, Grady, Terrence, Mehta, Paulette, Behler, Caroline, Hayes, Teresa G., Efebera, Yvonne A., Prabhala, Rao H., Han, Andrew, Yellapragada, Sarvari V., Klein, Catherine E., Roodman, Garson D., Lichtenstein, Alan, Munshi, Nikhil C.

“…Summary Once‐weekly administration of bortezomib has reduced bortezomib‐induced peripheral neuropathy without affecting response rates, but this has only been…”
Get full text

Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance by Blotta, Simona, Tassone, Pierfrancesco, Prabhala, Rao H., Tagliaferri, Piersandro, Cervi, David, Amin, Samir, Jakubikova, Jana, Tai, Yu-Tzu, Podar, Klaus, Mitsiades, Constantine S., Zullo, Alessandro, Franco, Brunella, Anderson, Kenneth C., Munshi, Nikhil C.

“…The transformation from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) is thought to be associated with changes in immune…”
Get full text

Sleep-loss activates NLRP3 inflammasome-activity in astrocytes by increasing electroencephalogram slow-waves and activates microglia to increase NREM sleep amounts by Zielinski, Mark R, Prabhala, Rao H, Niznikiewicz, Madaleine M, Desrosiers, Gretchen

“…We previously found that NLRP3 inflammasome activity is a critical mechanism regulating sleep and slow-waves. Microglia and astrocytes play a major role in…”
Get full text

Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM) by Sperling, Adam Samuel, Derman, Benjamin Avi, Nikiforow, Sarah, Im, Soo-Yeon, Ikegawa, Shuntaro, Prabhala, Rao H., Rodriguez, Diego Hernandez, Li, Yifang, Quinn, David S., Pearson, David, Bu, Dexiu, Mataraza, Jennifer, Liegel, Jessica, D'Souza, Anita, Rispoli, Lawrence, Credi, Marc, Ritz, Jerome, Jakubowiak, Andrzej J., De Vita, Serena, Munshi, Nikhil C.

“…8004 Background: B cell maturation antigen (BCMA) targeted CAR-T cells are approved for RRMM. Long manufacturing time and high clinical demand limit access…”
Get full text

Investigation into aberrant B cell repertoire in myeloma on humoral immunity and patient survival by Potluri, Lakshmi Bhavani, Seah, Hannah, Bade, Vaishnavi Reddy, Krogman, Arthur, Acharya, Shree, Negroiu, Andreea Mihaela, Talluri, Srikanth, Vempati, Lakshmi Manasa, Iragavarapu, Pradyumna, Lee, Saem, Fulciniti, Mariateresa, Samur, Mehmet Kemal, Richardson, Paul G., Moreau, Philippe, Avet-Loiseau, Herve, Anderson, Kenneth Carl, Prabhala, Rao H., Munshi, Nikhil C.

“…8016 Background: B cells are critical to inhibiting tumor progression, as they generate tumor-reactive antibodies; promote anti-tumor killing capacity of NK…”
Get full text

The effects of 13-cis-retinoic acid and beta-carotene on cellular immunity in humans by Prabhala, R H, Garewal, H S, Hicks, M J, Sampliner, R E, Watson, R R

“…Deficiency of vitamin A and/or its precursors has been associated with increased cancer risk in animals and humans. Therapeutic trials of vitamin A and related…”
Get more information

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group by Raje, Noopur S, Anaissie, Elias, Kumar, Shaji K, Lonial, Sagar, Martin, Thomas, Gertz, Morie A, Krishnan, Amrita, Hari, Parameswaran, Ludwig, Heinz, O'Donnell, Elizabeth, Yee, Andrew, Kaufman, Jonathan L, Cohen, Adam D, Garderet, Laurent, Wechalekar, Ashutosh F, Terpos, Evangelos, Khatry, Navin, Niesvizky, Ruben, Yi, Qing, Joshua, Douglas E, Saikia, Tapan, Leung, Nelson, Engelhardt, Monika, Mothy, Mohamad, Branagan, Andrew, Chari, Ajai, Reiman, Anthony J, Lipe, Brea, Richter, Joshua, Rajkumar, S Vincent, Miguel, Jesús San, Anderson, Kenneth C, Stadtmauer, Edward A, Prabhala, Rao H, McCarthy, Phillip L, Munshi, Nikhil C

“…Infection remains the leading cause of morbidity and mortality in patients with multiple myeloma because of the cumulative effect of disease, treatment, and…”
Get full text